The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ <scp>ENCORE</scp> Study)
The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study)
Kazuyuki Numakura, Tomokazu Sazuka, Sei Naito, Atsushi Mizokami et al.
Citations
4 citations
Journal
International Journal of Urology
Topics
Renal cell carcinoma treatment
Field-Weighted Citation Impact (FWCI)
6.07
article
The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study)
Kanazawa University (JP), Yamagata University (JP), Chiba University (JP), Akita University (JP), Hokkaido University (JP), Nagoya City University (JP), Juntendo University (JP), Ono Pharmaceutical (Japan) (JP), Tokyo Women's Medical University Adachi Medical Center (JP), Bristol-Myers Squibb (Japan) (JP), Nippon Medical School Hospital (JP), Nagasaki University (JP), Saitama Medical University (JP), Kindai University (JP)
Funders
Bristol-Myers Squibb, Japanese Urological Association, Ono Pharmaceutical
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ <scp>ENCORE</scp> Study) — Kazuyuki Numakura, Tomokazu Sazuka, et al. · International Journal of Urology (2025) | TGRS Research Map | TGRS